Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

INVO Bioscience, Inc. (IVOB.OB) – Positive Data Results Support Worldwide Marketing Expansion

|Includes: INVO BioScience, Inc. (IVOB)

INVO Bioscience Inc., a medical device company focused on treatment options for patients diagnosed with infertility, today announced that Dr. Elkin Lucena of the Columbian Fertility and Sterility Center’s (CECOLFES LTDA) in Columbia recently presented the results of 95 fertility treatment cycles involving INFO Bioscience’s INVOcell process. Results were presented at the 66th Annual Meeting of the American Society of Reproductive Medicine (ASRM) in Denver.

INVOcell is INVO Bioscience’s leading medical device, used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity.

The results of CECOLFES’s study demonstrated clinical pregnancy rates of 43 percent with each INVOcell cycle, and a 48 percent clinical pregnancy rate when an embryo has been transferred in the cycle. Efficacy rates were achieved in cycles completed in women from ages 21 to 45; the clinical pregnancy rate for patients aged 40 and younger was 46 percent, matching efficacy rates of currently used infertility treatments.

Claude Ranoux, MD, MS, president and chief scientific officer for INVO Bioscience, said CECOLFES’s results matched those of the company’s studies and outlined the importance of the results.

“We are delighted with the results presented by the Colombian Fertility and Sterility Center and Dr. Lucena. These results are consistent with our in-house data. It is important to note that in the INVOcell process significantly fewer eggs are recruited from patients, which decreases the risk of multiple births and reduces the number of premature births,” Dr. Ranoux stated in the press release. “Combining the comparative cost advantage of the INVOcell treatment versus current treatment regimes, and the ability to significantly reduce the occurrence of multiple pregnancies and their substantial incremental costs, positions INVOcell as an important therapy for infertility patients. The INVO procedure can generate outstanding results while significantly bringing down fertility treatment costs. We are very pleased with these results.”

INVO Bioscience said INVOcell is CE Mark approved in Europe and Canada and meets all consumer health and safety requirements. The device is currently marketed and sold in Austria, Canada, Cameroon, Columbia, Dominican Republic, Guatemala, Nicaragua, Pakistan, Panama, Peru, Spain, Togo, Turkey and Venezuela.

Dr. Ranoux said the results show INVOcell as a global solution to infertility issues and that the company will continue to extending its market reach.

“The report of these results is an important development in the history of the INVOcell device and process. The presentation of the positive results of this data at the prestigious ASRM Annual Meeting represents a powerful affirmation by one of the renowned pioneers in the fertility field, Dr. Lucena, as an effective, safe, and cost efficient technology. The INVO procedure will address a problem that affects millions of infertile patients worldwide. We look forward to leveraging this event as we continue our efforts to widely commercialize this revolutionary alternative for deserving patients in need of these life-fulfilling treatments,” he stated.

For more information visit invobioscience.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net



Disclosure: no positions